The 10,000 Brains Project is a nonprofit initiative dedicated to advancing targeted therapies for the millions of people affected by neurodegenerative diseases worldwide. By working across neurodegenerative diseases and harnessing the full potential of innovative tools and technologies, we aim to accelerate breakthroughs in earlier detection and more personalized care.
We envision a future where innovative technologies—such as artificial intelligence (AI) and big data analytics— unlock new insights across neurodegenerative disorders, enabling earlier detection and more personalized treatment for all patients.
The 10,000 Brains Project was created in 2023 by Kathy Harvard, Michael Maynard, and Everett Cook, three passionate, longtime patient advocates whose family and friends had been affected by various neurodegenerative diseases. What started as an effort to raise greater awareness about brain diseases quickly evolved into a plan for real action. Seeking a greater sense of urgency and more progress toward the cures patients need, they founded The 10,000 Brains Project to drive change in the way research is done.
Patrick Brannelly has a long track as a leader and change agent in neuroscience. He had previously worked with the founders on other initiatives over the years and was an informal advisor to them as they incubated The 10,000 Brains Project. He joined them as the organization’s founding CEO in 2023. Pat is passionate about bringing neuroscience research into the digital age, creating the conditions for breakthroughs that more traditional approaches could never achieve.
10,000 Brains is proof that when personal experience meets visionary leadership, real change is possible. And this movement isn’t limited to scientists or advocates— there is space for everyone to play a role in reshaping the future of neurodegenerative disease research.

Patrick Brannelly
CEO and Board Member

Mukta Phatak
Vice President of Data Strategy

Everett Cook
Co-Chair of the Board

Kathy Harvard
Board Member

David Kemp
Board Member and Treasurer

Oliver Kennan
Board Member and Secretary

Michael Maynard
Co-Chair of the Board

Ralph Terkowitz
Board Member
Professor of Pharmaceutical Chemistry
The University of California, San Francisco
Professor of Pathology and Neuroscience
The Icahn School of Medicine at Mount Sinai, NY
Executive Director
Chief Science Officer
CurePSP
Chief AI Officer
Eli Lilly and Company
Professor of Neurology
Chairman of Neurology
The Perelman School of Medicine at
the University of Pennsylvania
Professor of Neurology
Pathology Director
Boston University CTE Center
Director, Friedman Brain Institute
Chief Scientific Officer
The Icahn School of Medicine
at Mount Sinai, NY
Professor of Neurology and Pathology
The Memory and Aging Center
The University of California, San Francisco
Assistant Professor of Neuroscience at the Brain Science Institute
Associate Director of the JHU Single-Cell Training and Analysis Center
Johns Hopkins University
Scientific Director
Neural Stem Cell Institute University at Albany
State University of New York
Professor of Pharmaceutical Chemistry
The University of California, San Francisco